30 April 2012

Group I, Part II: H. Gillies: The collective experience in previous PAH: what needs to be considered related to trial design for future studies?

All credits to Dr. H. Gillies, Gilead Sciences Inc., San Francisco Bay Area CA, USA

Presentation at the 2nd PVRI/FDA Conference, Bethesda, Washington DC, April 30-May 1st 2012


Additional key-words:  end points,introduction,6MWD,imaging,biomarkers

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI